About the Study

Langerhans Cell Histiocytosis (LCH): Treatment study for Children and Adolescents

This study is being done for children and adolescents: • age 17 or younger. • Diagnosed with Langerhans Cell Histiocytosis (LCH) The purpose of this research study is to find out if extending the treatment even further (from 12 months to 24 months) and adding another drug called 6-mercaptopurine will result in fewer LCH relapses (when the disease comes back) and fewer long-term disease-related problems. Study patients will receive study treatment for about 12 or 24 months. After treatment, study patients will then be followed for at least 5 years.

Interested in learning more?

Full Study Name: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis